Press Releases

Date Title and Summary Additional Formats
Toggle Summary FDA Accepts IND Application for Radius Health's Investigational Drug RAD1901 Being Developed for Potential Use in Metastatic Breast Cancer
WALTHAM, Mass. , Dec. 19, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's Investigational New Drug (IND) application for its investigational drug RAD1901, a tissue-selective estrogen receptor
Toggle Summary FDA Approves Radius Health's TYMLOS™ (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
TYMLOS is the first new anabolic (bone building) agent for postmenopausal women with osteoporosis in the United States in nearly 15 years US Commercial Launch in May Approval Based on Results at 18 months from the Landmark ACTIVE Trial and the first six months of ACTIVExtend Trial Nearly One in Two
Toggle Summary Fractured Truth Campaign Wins Bronze Pearl Award for Content Marketing Excellence in the Healthcare/Pharmaceutical Industry
      WALTHAM, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) today announced that Fractured Truth—an unbranded patient campaign aimed to educate younger postmenopausal women about risks associated with osteoporosis—won the Bronze Healthcare/Pharmaceutical Industry Pearl
Toggle Summary Investigational Drug Abaloparatide Reduces the Incidence of Fractures in Postmenopausal Women With Osteoporosis
Radius Health announces positive Phase 3 data from the ACTIVExtend trial presented at the American Society for Bone and Mineral Research (ASBMR) 2015 Annual Meeting First six months of top-line data from ACTIVExtend show that treatment with investigational drug abaloparatide-SC followed by
Toggle Summary JAMA Publishes Positive Phase 3 Data for Abaloparatide in Postmenopausal Women With Osteoporosis
Results from Phase 3 ACTIVE trial show abaloparatide significantly reduced the incidence of new vertebral fractures and nonvertebral fractures in postmenopausal women with osteoporosis at 18 months when compared with placebo
Toggle Summary Mayo Clinic Proceedings Publishes Positive Results from the ACTIVExtend Clinical Trial of Abaloparatide-SC in Postmenopausal Women With Osteoporosis
— Results from interim analysis of the ACTIVExtend study of postmenopausal women with osteoporosis treated for 18 months with investigational drug abaloparatide-SC in the ACTIVE trial who were transitioned to alendronate in ACTIVExtend show statistically significant reductions at six months in the
Toggle Summary New Analysis from ACTIVE Showed Consistent Fracture Reductions for Abaloparatide-SC Across Geographies
The data was presented in an Oral Late-Breaker at Annual Endocrine Society Meeting "ENDO 2017" on April 1 Additional analysis of BMD gains at the wrist and fracture reductions  at the ultradistal radius compared to placebo and teriparatide were presented on April 2 WALTHAM, Mass., April 03, 2017
Toggle Summary New National Survey Reveals 82 Percent of Postmenopausal Women Miss Critical Connection Between Osteoporosis and Bone Fractures
Joint Survey from National Osteoporosis Foundation, HealthyWomen and Radius Health Sounds an Urgent Call to Action for Women to Know Their Risk, Get the Facts ‘Fractured Truth' Education Campaign Addresses Entrenched Misperceptions, Asks Women to Rethink Their Beliefs About Bone Health WALTHAM,
Toggle Summary Radius Announces Appointment of Michael Franken as Senior Vice President and Chief Business Officer
Radius Announces Appointment of Michael Franken as Senior Vice President and Chief Business Officer CAMBRIDGE, Mass., April  20, 2011—   Radius Health, Inc., a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women's health
Toggle Summary Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study View HTML